Under the theme “Step into the Future: The Next AI Frontier,” the swisstech Pavilions feature groundbreaking technologies across AI & Robotics, Cleantech, Cybersecurity, Fintech, Healthtech, ICT and Gaming/XR. 24 visionary start-ups and global leaders showcase how Switzerland drives innovation worldwide.
SWISS Pavilion
Switzerland at BIO 2025: Innovation, Collaboration, and Global Impact Welcome to the SWISS Pavilion at BIO International Convention 2025 – your gateway to one of the world’s most dynamic and resilient biotech ecosystems. Switzerland stands at the forefront of global biotechnology, driven by a unique blend of scientific excellence, international collaboration, and a deep commitment to innovation that benefits patients and partners worldwide. Switzerland’s biotech industry continues to demonstrate remarkable strength and adaptability. According to the Swiss Biotech Report 2025, the sector attracted CHF 2.5 billion in capital investment in 2024 – a 22% increase over the previous year – despite global economic headwinds. This growth reflects the confidence of international investors in Swiss innovation and the country’s ability to deliver breakthrough solutions in healthcare, diagnostics, and life sciences. With over 1,000 biotech companies and a dense network of academic institutions, research centers, and global pharma leaders, Switzerland offers a fertile environment for biotech innovation. The industry contributes significantly to the national economy, with life sciences accounting for over 50% of Swiss exports. This year’s Swiss Biotech Report emphasizes the importance of international collaboration. Four out of five biotech patents filed in Switzerland are the result of cross-border partnerships. Swiss companies are not only developing therapies for the local market – they are building global business cases, forming strategic alliances, and co-developing solutions that address some of the world’s most pressing health challenges. At the SWISS Pavilion, you’ll find a curated selection of Switzerland’s most promising biotech innovators – from agile startups and academic spin-offs to established scale-ups and research-driven SMEs. While each exhibitor brings a unique value proposition, together they represent the full spectrum of Swiss biotech excellence: – Next-generation therapeutics: From immuno-oncology to gene and cell therapies, Swiss companies are advancing novel treatment modalities with global potential. – Cutting-edge diagnostics: Precision medicine is a key focus, with technologies that enable earlier, more accurate, and personalized diagnosis. – Digital health and AI: Swiss innovators are integrating data science and machine learning into biotech workflows, accelerating discovery and improving patient outcomes. – Sustainable biomanufacturing: Several exhibitors are pioneering green biotech solutions and scalable production platforms. – Academic and regional clusters: The Pavilion also features representatives from Switzerland’s leading biotech hubs, including the Basel Area, the Greater Zurich Area, and Greater Geneva Bern area, showcasing the country’s decentralized yet interconnected innovation landscape. Why visit the SWISS Pavilion? – Meet high-potential partners: Engage with companies actively seeking international collaborations, licensing opportunities, and investment. – Explore innovation across the value chain: From early-stage research to clinical development and commercialization. – Experience Swiss quality and reliability: A hallmark of Swiss biotech is its commitment to scientific rigor, regulatory excellence, and long-term partnerships. Whether you’re looking for your next strategic partner, investment opportunity, or simply want to explore the future of biotech, the SWISS Pavilion is your destination at BIO 2025. Join us in shaping the future of global health – the Swiss way. | Switzerland at BIO 2026: Innovation, Collaboration, and Global Impact Welcome to the SWISS Pavilion at BIO International Convention 2026 – your gateway to one of the world’s most dynamic and resilient biotech ecosystems. Switzerland stands at the forefront of global biotechnology, driven by a unique blend of scientific excellence, international collaboration, and a deep commitment to innovation that benefits patients and partners worldwide. Switzerland’s biotech industry continues to demonstrate remarkable strength and adaptability. According to the Swiss Biotech Report 2025, the sector attracted CHF 2.5 billion in capital investment in 2024 – a 22% increase over the previous year – despite global economic headwinds. This growth reflects the confidence of international investors in Swiss innovation and the country’s ability to deliver breakthrough solutions in healthcare, diagnostics, and life sciences. With over 1,000 biotech companies and a dense network of academic institutions, research centers, and global pharma leaders, Switzerland offers a fertile environment for biotech innovation. The industry contributes significantly to the national economy, with life sciences accounting for over 50% of Swiss exports. This year’s Swiss Biotech Report emphasizes the importance of international collaboration. Four out of five biotech patents filed in Switzerland are the result of cross-border partnerships. Swiss companies are not only developing therapies for the local market – they are building global business cases, forming strategic alliances, and co-developing solutions that address some of the world’s most pressing health challenges. At the SWISS Pavilion, you’ll find a curated selection of Switzerland’s most promising biotech innovators – from agile startups and academic spin-offs to established scale-ups and research-driven SMEs. While each exhibitor brings a unique value proposition, together they represent the full spectrum of Swiss biotech excellence: – Next-generation therapeutics: From immuno-oncology to gene and cell therapies, Swiss companies are advancing novel treatment modalities with global potential. – Cutting-edge diagnostics: Precision medicine is a key focus, with technologies that enable earlier, more accurate, and personalized diagnosis. – Digital health and AI: Swiss innovators are integrating data science and machine learning into biotech workflows, accelerating discovery and improving patient outcomes. – Sustainable biomanufacturing: Several exhibitors are pioneering green biotech solutions and scalable production platforms. – Academic and regional clusters: The Pavilion also features representatives from Switzerland’s leading biotech hubs, including the Basel Area, the Greater Zurich Area, and Greater Geneva Bern area, showcasing the country’s decentralized yet interconnected innovation landscape. Why visit the SWISS Pavilion? – Meet high-potential partners: Engage with companies actively seeking international collaborations, licensing opportunities, and investment. – Explore innovation across the value chain: From early-stage research to clinical development and commercialization. – Experience Swiss quality and reliability: A hallmark of Swiss biotech is its commitment to scientific rigor, regulatory excellence, and long-term partnerships. Whether you’re looking for your next strategic partner, investment opportunity, or simply want to explore the future of biotech, the SWISS Pavilion is your destination at BIO 2026. Join us in shaping the future of global health – the Swiss way. | Swissenviro was founded in 2015 by Urs Heutschi. It is a small, privately-owned company and the organizer of the SWISS Pavilion at international trade fairs for environmental technologies. With more than 20 years of experience, the international fair work is our area of expertise and forms the core of our work. The aim is to support export-orientated Swiss Cleantech SME to find buyers and business partners in international markets by encouraging international networking and direct B2B contacts on trade fairs and other events. By participation in a Joint Swiss Booth, the “SWISS Pavillon”, we are bringing together Swiss SMEs with professional trade visitors – potential future buyers, partners or suppliers. If desired, we gladly accompany and support the SME further on its business project resulting from this first customer contact. We closely work together with relevant Swiss environmental associations such as Cleantech Alps, VSA and Energie-Cluster. For our SWISS Pavilions we are supported by the MPK from “Switzerland Global Enterprise” (S-GE) and the “Swiss Federal Office for the Environment” (FOEN).
Suzhou Recodeal Interconnect System Co., Ltd.
Recodeal Interconnect Systems is a global leader in high-voltage connectors, busbars, and custom interconnect solutions engineered for e-mobility, energy storage, and battery applications. With over two decades of expertise in OEM manufacturing, we deliver vertically integrated, rapid-turn solutions from our facilities across North America, China, and Southeast Asia. Our product lines include EV battery connectors, LV/HV busbars, injection molded components, and precision stamped parts — designed for automotive, commercial vehicles, industrial energy systems, communications, and robotics. At Booth 5150, discover how Recodeal’s agile engineering, global supply chain, and commitment to quality accelerate your product development and production timelines. Partner with us to power the future of electrification.
Suven Life Sciences Limited
Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer’s disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson’s disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer’s type (Global Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study in progress). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.
Sussex Research Laboratories Inc.
Sussex Research Laboratories Inc. (Ottawa, Canada) is a globally recognized specialist in empowering therapeutic innovation through glycoscience. The company applies its expertise in glycodesign, glycan and glycoconjugate synthesis, and linker chemistries across a wide range of therapeutic areas, including vaccine development, protein and antibody engineering, and targeted drug delivery. With 30 years of experience as a Contract Research & Development (CRO) service provider, Sussex Research supports pharmaceutical and biopharmaceutical partners in applying glycotechnology to next-generation therapeutics, including oligonucleotide, peptide, protein, lipid, and small-molecule modalities, as well as lipid nanoparticle (LNP) technologies for modern drug design and delivery. The company is also widely recognized for its enabling product portfolio of advanced glycans, glycopeptides, glycoconjugates, and targeting ligand/linker systems.
SurTec, Inc.
SurTec – Your Partner for Surface Treatment Solutions in E-MobilitySurTec develops, manufactures, and supplies chemical specialities for surface treatment, offering a comprehensive portfolio for the battery, EV, and automotive industries. Our expertise covers the full range of applications – from industrial parts cleaning and metal pretreatment to functional and decorative electroplating.For battery systems and electric drivetrain components, SurTec provides advanced sealing & locking solutions, corrosion protection, and anti-friction coatings tailored to demanding environmental and performance standards. Our solutions are engineered for high durability, reliability, and sustainability – critical in modern e-mobility.With decades of experience, global technical centers, and a strong commitment to innovation, SurTec supports customers in optimizing surface processes along the entire value chain.www.surtec.com | A company of Freudenberg Chemical Specialities
Surmodics Inc.
Biocoat Incorporated has been advancing hydrophilic coating technology for over 30 years, serving medical device manufacturers worldwide with industry-leading coatings, and services. Its proprietary coating solutions are designed to improve lubricity, durability, and particulate counts across a wide range of interventional and diagnostic devices. From feasibility testing through large-scale production, Biocoat provides a comprehensive pathway for innovators to bring safer, more effective devices to market. | Surmodics, Inc. a global leader of novel surface modification has recently commercialized its most advanced hydrophilic coating known as Preside™ to significantly improve the track-ability, cross-ability, and push-ability for minimally invasive catheter or guidewire programs (or requirements). The company’s technologies include lubricious, hemocompatible, and drug delivery (polymer matrix) platforms. Our technical services include commercial development, coating services, premixed solutions, and technology transfers. | Surmodics, Inc. a global leader of novel surface modification has recently commercialized its most advanced hydrophilic coating known as Preside™ to significantly improve the track-ability, cross-ability, and push-ability for minimally invasive catheter or guidewire programs (or requirements). The company’s technologies include lubricious, hemocompatible, and drug delivery (polymer matrix) platforms. Our technical services include commercial development, coating services, premixed solutions, and technology transfers.
SurePay
SurePay Founded in 2016, SurePay is the leading account verification platform, built for fraud prevention and payment accuracy. Relied upon by 250+ banks and 20,000+ organizations across 16 countries, we verify beneficiary details in real-time before money moves, detecting risk, preventing loss, and ensuring every payment reaches the right recipient, first time. Our network scale is what makes our platform the smartest. surepay.eu
SUPERA PARQUE
SUPERA Park is an innovative environment that promotes knowledge transfer in several types of activities. It is responsible for attracting and retaining technology-based companies, with noteworthy mention to the Health, Biotechnology, Information Technology and Bioenergy industries. SUPERA Park was built within the University of São Paulo (USP) – one of the best universities in Brazil, Fact that makes it easier to find qualified people and hard science knowledge. SUPERA Park has many activities to support startups to validate and build a solid business model. Based on this, we have one of the best business incubator in Brazil (top 20 world universities in the 2019 UBI benchmark), 9 different laboratories for technical tests and validation, an international department and 3 clusters (health, software and beer) supported by our team. We also represent a number of startups that are looking for new partnerships and customers for their solutions. | SUPERA is the technology park of Ribeirão Preto, one of the most important scientific centers in the country. Our main programs are the Business Incubator, Open Innovation Program and Softlanding Program for international companies wishing to settle in Brazil. | SUPERA Innovation and Technology Park is a dynamic innovation ecosystem located in Ribeirão Preto, São Paulo, Brazil, and is linked to the University of São Paulo (USP) – Ribeirão Preto campus. SUPERA Park is a reference center for science, technology, and innovation, fostering entrepreneurship, knowledge-based businesses, and technological development. Core Mission: SUPERA Park supports the development and growth of startups, scale-ups, and innovative companies, particularly in the fields of biotechnology, life sciences, health, information technology, and advanced manufacturing. It provides infrastructure, business development support, and access to networks that drive innovation and competitiveness. Key Activities and Services: – Business Incubation and Acceleration: Programs for startups and scale-ups, offering mentoring, business modeling, market validation, and growth strategies. – Softlanding Programs: Support for international companies entering the Brazilian market and Brazilian companies aiming to internationalize. – Collaborative R&D Support: Facilitation of partnerships between companies, universities, and research centers for research, development, and innovation (R&D&I) projects. – Innovation Programs: Open innovation initiatives connecting corporations with startups and researchers to solve business challenges. – Infrastructure: High-standard office spaces, laboratories, coworking areas, and access to specialized facilities in biotechnology, pharmaceuticals, agritech, healthtech, and ICT. – Matchmaking and Networking: Connection to investors, corporate partners, academic experts, and government agencies to foster business and technology development. – International Cooperation: Support for international collaborative projects, technology transfer, and partnerships with global innovation ecosystems. Key Sectors of Focus: – Biotechnology – Pharmaceuticals and HealthTech – Medical Devices – Agritech and Bioinputs – Digital Health and ICT – Clean Technologies